Search Results



Your search for Christoph Zielinski, MD matches 6 pages

Showing 1 - 6


First ESMO Award for Immuno-Oncology Presented to Laurence Zitvogel, MD, PhD

The European Society for Medical Oncology (ESMO) has granted the newly established ESMO Award for Immuno-Oncology to Laurence Zitvogel, MD, PhD, for her innovating and internationally recognized achievements in the field. Dr. Zitvogel is Professor of Immunobiology at the University of Paris XI...

breast cancer

Bevacizumab/Capecitabine vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Christoph Zielinski, MD, of the Medical University of Vienna and the Central European Cooperative Oncology Group, and colleagues, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine...

breast cancer

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...

global cancer care

Christoph Zielinski, MD: Highlights of 2015 European Cancer Congress

As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.

breast cancer

French Investigators Prospectively Test Genomically Driven Treatment in Metastatic Breast Cancer 

Whole-genome DNA analysis prospectively identified alterations in metastatic tumors that could be individually targeted with molecular agents, in a study presented at the 2012 European Society for Medical Oncology (ESMO) Congress by Fabrice André, MD, of Institut Gustave-Roussy, Villejuif, France. ...

issues in oncology
cost of care

ESMO Asia 2015: Cancer Drives Patients to Poverty in Southeast Asia

Five percent of cancer patients and their families were pushed into poverty in Southeast Asia between March 2012 and September 2013 because of high disease-related costs, a study (Abstract 52O) by Bhoo-Pathy et al at the European Society for Medical Oncology (ESMO) Asia 2015 Congress in Singapore...

Advertisement



Advertisement


Advertisement